Methadone treatments in a Swiss Region, 2001–2008: a registry-based analysis

BMC Psychiatry

Françoise Dubois-Arber¹  Valentin Rousson¹  Thérèse Huissoud¹ 

[1] Institute of Social and Preventive Medicine, University Hospital Centre and University of Lausanne, Biopole 2 Route de la Corniche 10, CH – 1010, Lausanne, Switzerland

关键词: Switzerland;    Treatment interruption;    Treatment duration;    Methadone registry;    Methadone maintenance;    Opioid substitution;   

Others  :  1124194
DOI  :  10.1186/1471-244X-12-238

 received in 2012-05-24, accepted in 2012-12-19,  发布年份 2012

【 摘 要 】

Background

To determine, in a region of Switzerland, the duration of retention in opioid substitution treatments with methadone (OSTM), duration of treatment interruptions, probability of re-entry to treatment after a treatment interruption, and associated factors.

Methods

A secondary analysis of registry-based data was performed with patients (n = 2880) registered in the methadone treatment register database of the Public Health Service of the canton of Vaud between January 1, 2001 and June 30, 2008. Survival analysis and multivariate analysis was conducted.

Results

The probability of remaining on treatment was 69% at 1 year and 45% at 3 years (n =1666). One-third of patients remained on treatment beyond 5 years. The estimated hazard of leaving treatment was increased by a ratio of 1.31 in the case of a first treatment (P = 0.001), 1.83 for those without a fixed home (P < 0.001), and 1.29 for those younger than 30 years old (P < 0.001). The probability of having begun a new treatment after a first interruption was 21% at one year, 38% at 3 years, and 43% at 5 years (n = 1581). Factors at the interruption of treatment associated with a higher probability of re-entering were: interruption not due to methadone withdrawal, bad physical health, and higher methadone dose.

Conclusions

OSTM are long-term (maintenance) treatments in Switzerland. Younger age, bad living conditions at entry, and first treatment are predictors of lower retention. Approximately one-half of patients who interrupt treatment will re-enter treatment within 5 years.

【 授权许可】

   
2012 Huissoud et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 5.

【 参考文献 】

• [1]Schorr D, Künzi U: Was sagt uns die methadonstatistik über die Entwicklung der letzten Jahre? Ein Vergleich zwischen ausgewählten Kantonen [What do the methadone statistics tell us about developments over the last few years?]. Abhängigkeiten 2007, (3):22-31.
• [2]Die Nationale Methadonstatistik. Bern: Bundesamt für Gesundheitswesen (BAG); 2010.
• [3]Hosek M: Substitutionsbehandlungen in der Schweiz: Fortsetzung einer Erfolgsgeschichte. Suchtmagazin 2006, 1:3-9.
• [4]Waal H: Merits and problems in high-threshold methadone maintenance treatment. Evaluation of medication-assisted rehabilitation in Norway 1998–2004. Eur Addict Res 2007, 13(2):66-73.
• [5]Jarvinen M: Approaches to methadone treatment: harm reduction in theory and practice. Sociol Health Illn 2008, 30(7):975-991.
• [6]Herrmann H: Aktuelle Praxis der Substitutionsbehandlung mit Methadon in der Schweiz 2000. Basel: Gesamtschweizerische Erhebung bei den an der ärtzlichen Opiatverschreibung Beteiligten une Betroffenen; 2001.
• [7]Zarkin GA, Dunlap LJ, Hicks KA, Mamo D: Benefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ 2005, 14(11):1133-1150.
• [8]Termorshuizen F, Krol A, Prins M, van Ameijden EJ: Long-term outcome of chronic drug use: the Amsterdam Cohort Study among Drug Users. Am J Epidemiol 2005, 161(3):271-279.
• [9]Termorshuizen F, Krol A, Prins M, Geskus R, van den Brink W, van Ameijden EJ: Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. Drug Alcohol Depend 2005, 79(2):231-240.
• [10]Hser YI, Hoffman V, Grella CE, Anglin MD: A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry 2001, 58(5):503-508.
• [11]Swiss Society of Addiction Medicine: Substitution-assisted treatment in opioid dependence. Summary of the clinical recommendations for Substitution-assisted treatment (SAT) in opioid dependence issued by the SSAM (Swiss Society of Addiction Medicine) in 2007. Bern: Federal Office of Public Health; 2010.
• [12]Service de la santé publique du canton de Vaud: Directives du Médecin cantonal concernant la prescription, la dispensation et l’administration des stupéfiants destinés à la prise en charge de personnes dépendantes (état le 01.05.2010). Lausanne: Département de la santé et de l’action sociale du canton de Vaud; 2010.
• [13]Mancino M, Curran G, Han X, Allee E, Humphreys K, Booth BM: Predictors of attrition from a national sample of methadone maintenance patients. Am J Drug Alcohol Abuse 2010, 36(3):155-160.
• [14]Burns L, Randall D, Hall WD, Law M, Butler T, Bell J, Degenhardt L: Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Addiction 2009, 104(8):1363-1372.
• [15]Bell J, Trinh L, Butler B, Randall D, Rubin G: Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009, 104(7):1193-1200.
• [16]Davstad I, Stenbacka M, Leifman A, Beck O, Korkmaz S, Romelsjo A: Patterns of illicit drug use and retention in a methadone program: a longitudinal study. J Opioid Manag 2007, 3(1):27-34.
• [17]Perreault M, Heroux MC, White ND, Lauzon P, Mercier C, Rousseau M: Treatment retention and evolution of clientele in a low threshold methadone substitution treatment program in Montreal. Can J Public Health 2007, 98(1):33-36.
• [18]Michels II, Stover H, Gerlach R: Substitution treatment for opioid addicts in Germany. Harm Reduct J 2007, 4:5. BioMed Central Full Text
• [19]Harris KA Jr, Arnsten JH, Joseph H, Hecht J, Marion I, Juliana P, Gourevitch MN: A 5-year evaluation of a methadone medical maintenance program. J Subst Abuse Treat 2006, 31(4):433-438.
• [20]Gossop M, Marsden J, Stewart D, Treacy S: Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend 2001, 62(3):255-264.
• [21]Havens JR, Latkin CA, Pu M, Cornelius LJ, Bishai D, Huettner S, Rapp C, Ricketts EP, Lloyd JJ, Strathdee SA: Predictors of opiate agonist treatment retention among injection drug users referred from a needle exchange program. J Subst Abuse Treat 2009, 36(3):306-312.
• [22]Magura S, Nwakeze PC, Demsky SY: Pre- and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction 1998, 93(1):51-60.
• [23]Magura S, Rosenblum A: Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med 2001, 68(1):62-74.
• [24]Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP: An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005, 28(4):321-329.
• [25]Esteban J, Gimeno C, Barril J, Aragones A, Climent JM, de la Cruz Pellin M: Survival study of opioid addicts in relation to its adherence to methadone maintenance treatment. Drug Alcohol Depend 2003, 70(2):193-200.
• [26]Nosyk B, MacNab YC, Sun H, Fischer B, Marsh DC, Schechter MT, Anis AH: Proportional hazards frailty models for recurrent methadone maintenance treatment. Am J Epidemiol 2009, 170(6):783-792.
• [27]Salamina G, Diecidue R, Vigna-Taglianti F, Jarre P, Schifano P, Bargagli AM, Davoli M, Amato L, Perucci CA, Faggiano F: Effectiveness of therapies for heroin addiction in retaining patients in treatment: results from the VEdeTTE study. Subst Use Misuse 2010, 45(12):2076-2092.
• [28]Macarthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, Degenhardt L, Hickman M: Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ 2012, 345:e5945.
• [29]Che Y, Assanangkornchai S, McNeil E, Chongsuvivatwong V, Li J, Geater A, You J: Predictors of early dropout in methadone maintenance treatment program in Yunnan province, China. Drug Alcohol Rev 2010, 29(3):263-270.
• [30]Strike CJ, Gnam W, Urbanoski K, Fischer B, Marsh DC, Millson M: Factors predicting 2-year retention in methadone maintenance treatment for opioid dependence. Addict Behav 2005, 30(5):1025-1028.
• [31]Goldstein A, Herrera J: Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up. Drug Alcohol Depend 1995, 40(2):139-150.
• [32]Gossop M, Green L, Phillips G, Bradley B: Lapse, relapse and survival among opiate addicts after treatment. A prospective follow-up study. Br J Psychiatry 1989, 154:348-353.
• [33]Ball JC, Ross A (Eds): The effectiveness of methadone maintenance treatment: patients, programs, services and outcome. New York; Berlin etc: Springer-Verl; 1991.
• [34]Bell J, Burrell T, Indig D, Gilmour S: Cycling in and out of treatment; participation in methadone treatment in NSW, 1990–2002. Drug Alcohol Depend 2006, 81(1):55-61.
• [35]Fugelstad A, Stenbacka M, Leifman A, Nylander M, Thiblin I: Methadone maintenance treatment: the balance between life-saving treatment and fatal poisonings. Addiction 2007, 102(3):406-412.
• [36]Clausen T, Waal H, Thoresen M, Gossop M: Mortality among opiate users: opioid maintenance therapy, age and causes of death. Addiction 2009, 104(8):1356-1362.
• [37]Huissoud T, Gumy C, Gervasoni J-P, Dubois-Arber F: Analyse de la statistique des traitements à la méthadone dans le canton de Vaud: Période 2001–2008. Lausanne: Institut universitaire de médecine sociale et préventive; 2010.